Aespira
VP Business Development
Mr. Ian Solomon –
ian.solomon@aespira.com
Aespira’s ActiveMesh® dry-powder inhaler (DPI) technology ensures simple, foolproof delivery of inhaled medications, with audible confirmation of dose delivery. This technology is based on a novel beating technology - not on turbulence – which provides the dose at the correct inhalation threshold.
It operates at very low pressure-drop across the device, enabling patients having only low “inspiratory pressure” to receive the drugs, and it delivers existing regular micronized powders and standard APIs (as opposed to engineered particles with a complex regulatory path).
The company’s single-dose disposable inhalers are designed for acute conditions, for example during an asthma or COPD attack where a single dose needs to be verifiably delivered, or where a multi-dose inhaler would prove costly and wasteful.
In addition to the consumer market, it is suitable for hospitals, clinics and nursing homes, where sterility, dose-management and prevention of cross-contamination is of utmost importance;
and for short term/single dose treatments for patients not requiring (or possessing) a multi-dose device.
Gidi Kahana, CEO,
Ian Solomon, VP Business Development,
Arie Holtz, VP R&D plus an impressive multinational Advisory Board and consulting team.
Aespira is developing a pipeline of simple-to-use dry-powder inhaler products for acute and rescue medical indications based on a proprietary product platform (the ActiveMesh®) enabling simple and foolproof usage.
The technology and device have been proven in-vitro in German and US labs, with device optimization being evaluated at Kiel University during 2010 / 2011.
The initial formulation work for the company’s first product has been performed, and the first generation filling machinery has been co-developed with industrial partner Harro Höfliger.
A short regulatory route to product approval has been designed, and patents have filed covering both the technology and the device. Next Step: Preparation for a First-in-Man (FIM) Bioequivalence Pilot Trial during 2012.
Aespira currently plans a fund raise of $1.5m to complete the FIM trial, broaden its pipeline, bring on board international marketing expertise and significantly enhance its value, prior to performing the pivotal trial and first product release.
In the short-term, the ccompany will develop and market resQhaler initial products in Europe and seek to out-license these first pipeline products to larger companies for the U.S. market.
These companies will then handle the regulatory process in the US through to FDA approval and product launch and marketing.
Sustained revenues from EU sales and these initial out-licensing deals will fund Aespira’s development of its other pipeline candidates to advanced stages, and will be used to create additional pipeline opportunities while decreasing dependency on capital market financing.
The company's targeted business partners include those pharmaceutical and biotechnology companies that have extensive experience with the clinical development, production and marketing of inhaler products.
In addition, Aespira may target smaller companies that have formulated generic products or branded products for the inhaler respiratory disease market. For some pipeline products, such second-tier companies could be strategic partners during product development.